menu
    • menu

    Company profile for SineuGene Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SineuGene Therapeutics is a biopharmaceutical company specializing in gene therapy for brain disorders. Founded in 2021, it builds on over a decade of neuroscience research by JiaLab at Tsinghua University. With expertise in gene expression, editing technology, and nucleic acid-mediated regulation, SineuGene is dedicated to developing treatments for neurological diseases, including ALS, stroke, Parkinson's, Alzheimer's, Huntin...
    SineuGene Therapeutics is a biopharmaceutical company specializing in gene therapy for brain disorders. Founded in 2021, it builds on over a decade of neuroscience research by JiaLab at Tsinghua University. With expertise in gene expression, editing technology, and nucleic acid-mediated regulation, SineuGene is dedicated to developing treatments for neurological diseases, including ALS, stroke, Parkinson's, Alzheimer's, Huntington's chorea, and autism spectrum disorder, aiming to transform patient care with innovative therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SineuGene TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    1st Floor, Building 15th, PKUCare Innovation Park, Life Park Road, Changping D...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sineugene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sineugene-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Global ChemShow

    Not Confirmed

    envelop Contact Supplier

    Global ChemShow

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ALS Gene Therapy Approved for Global Trials in China and U.S.
    ALS Gene Therapy Approved for Global Trials in China and U.S.

    15 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novel-gene-therapy-for-als-cleared-for-global-trials-in-china-and-the-us-302530807.html

    PR NEWSWIRE
    15 Aug 2025
    Share Share
    SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS
    SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS

    26 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sineugenes-snug01-receives-fda-orphan-drug-designation-for-als-302492342.html

    PR NEWSWIRE
    26 Jun 2025
    Share Share
    SineuGene Therapeutics gets FDA clearance for ALS gene therapy
    SineuGene Therapeutics gets FDA clearance for ALS gene therapy

    25 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sineugene-therapeutics-announces-fda-ind-clearance-for-snug01-a-first-in-class-trim72-targeted-gene-therapy-for-als-302408738.html

    PR NEWSWIRE
    25 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search